The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation
Open Access
- 2 July 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (27) , e21025
Abstract
Background: Given the huge burden of atrial fibrillation (AF) and AF-related stroke in Asia, stroke prevention represents an urgent issue in this region. We herein performed a network meta-analysis to examine the role of non-vitamin K antagonist oral anticoagulants (NOACs) in Asian patients with AF. Methods: A systematic search of the publications was conducted in PubMed and Embase databases for eligible studies until July 2019. The odds ratios (ORs) and 95% confidence intervals (CIs) were regarded as the effect estimates. The surface under the cumulative ranking area (SUCRA) for the ranking probabilities was calculated. Results: A total of 17 studies were included. For comparisons of NOACs vs warfarin, dabigatran (OR = 0.77, 95% CI 0.68–0.86), rivaroxaban (OR = 0.72, 95% CI 0.65–0.81), apixaban (OR = 0.56, 95% CI 0.49–0.65), but not edoxaban reduced the risk of stroke or systemic embolism, wheres dabigatran (OR = 0.56, 95% CI 0.41–0.76), rivaroxaban (OR = 0.66, 95% CI 0.50–0.86), apixaban (OR = 0.49, 95% CI 0.36–0.66), and edoxaban (OR = 0.34, 95% CI 0.24–0.49) decreased the risk of major bleeding. In reducing the risk of stroke or systemic embolism, apixaban and rivaroxaban ranked the best and second best (SUCRA 0.2% and 31.4%, respectively), followed by dabigatran (50.2%), edoxaban (75.2%), and warfarin (93.0%). In reducing the risk of major bleeding, edoxaban, and apixaban ranked the best and second best (1.5% and 30.8%, respectively), followed by dabigatran (48.4%), rivaroxaban (69.2%), and warfarin (100%). Conclusion: NOACs were at least as effective as warfarin, but more safer in Asians with AF. Apixaban was superior to other NOACs for reducing stroke or systemic embolism, while edoxaban showed a better safety profile than other NOACs.Keywords
This publication has 34 references indexed in Scilit:
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Graphical Tools for Network Meta-Analysis in STATAPLOS ONE, 2013
- Dabigatran Versus WarfarinStroke, 2013
- Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studiesResearch Synthesis Methods, 2012
- Rivaroxaban vs. Warfarin in Japanese Patients With Atrial FibrillationCirculation Journal, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009